Francesca Maria Rossi

8PUBLICATIONS
68CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)Haematological tumoursMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 14, 2025
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas.

Alberto J Arribas, Francesca Guidetti, Eleonora Cannas

|Jun 18, 2025
Measurement of Immunoglobulin Intraclonal diversification refines the clinical impact of IGHV mutational status in chronic lymphocytic leukemia.

Filippo Vit, Tamara Bittolo, Antonella Zucchetto

|Aug 14, 2024
The VLA-4 integrin is constitutively active in circulating chronic lymphocytic leukemia cells via BCR autonomous signaling: a novel anchor-independent mechanism exploiting soluble blood-borne ligands.

Erika Tissino, Annalisa Gaglio, Antonella Nicolò

|Jun 26, 2024
Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition.

Simone Mirabilii, Monica Piedimonte, Esmeralda Conte

|Dec 05, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.

Alberto J Arribas, Sara Napoli, Luciano Cascione

|Feb 22, 2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.

Riccardo Bomben, Francesca Maria Rossi, Filippo Vit

Pageof 2

Frequent Collaborators

7 joint publications

Valter Gattei

4 joint publications

Riccardo Bomben

3 joint publications

Alberto J Arribas

3 joint publications

Sara Napoli